Thoracic Cancer最新文献_第10页

A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902). 针对局部晚期非小细胞肺癌老年患者的每周卡铂和同期放化疗 II 期研究（LOGIK1902）。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1111/1759-7714.15444

Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, Shinnosuke Takemoto, Yasushi Hisamatsu, Haruhiro Saito, Yasuto Yoneshima, Kazutoshi Komiya, Kosuke Kashiwabara, Katsuhiko Naoki, Tomohiro Ogawa, Hiroaki Takeoka, Koichi Saruwatari, Kensaku Ito, Yuko Tsuchiya-Kawano, Keiko Mizuno, Takayuki Shimose, Yoshiyuki Shioyama, Isamu Okamoto

{"title":"A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).","authors":"Taishi Harada, Tomonari Sasaki, Hidenobu Ishii, Shinnosuke Takemoto, Yasushi Hisamatsu, Haruhiro Saito, Yasuto Yoneshima, Kazutoshi Komiya, Kosuke Kashiwabara, Katsuhiko Naoki, Tomohiro Ogawa, Hiroaki Takeoka, Koichi Saruwatari, Kensaku Ito, Yuko Tsuchiya-Kawano, Keiko Mizuno, Takayuki Shimose, Yoshiyuki Shioyama, Isamu Okamoto","doi":"10.1111/1759-7714.15444","DOIUrl":"10.1111/1759-7714.15444","url":null,"abstract":"Background: Concurrent chemoradiotherapy is the standard therapy for locally advanced non-small cell lung cancer (NSCLC). However, there is little evidence supporting its use in older adults. Low-dose daily carboplatin combined with thoracic radiotherapy is considered a standard regimen for this population. To establish a simple and feasible carboplatin administration method, we conducted a study of weekly carboplatin and concurrent radiotherapy for older adults with locally advanced NSCLC.Methods: This prospective, single-arm, multicenter, phase II clinical trial included patients aged ≥75 years with unresectable stage III NSCLC and Eastern Cooperative Oncology Group performance status 0-1. Patients received chemoradiotherapy (60 Gy/30 fractions plus concurrent weekly carboplatin at an area under curve of 2 mg mL-1 min-1). The primary endpoint was the overall response rate (ORR). Key secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.Results: From July 2020 to June 2022, 37 patients were enrolled from 15 institutions, and 36 patients were evaluable for efficacy and safety. The ORR was 63.9% (95% confidence interval [CI] = 47.6-77.5). Median PFS was 14.6 months (95% CI = 9.1-18.1). Median OS was 25.5 months (95% CI = 17.4-not reached). Grade 4 leucopenia, neutropenia, and thrombocytopenia were observed in one patient (2.8%) each.Conclusion: Weekly carboplatin and concurrent radiation therapy was safe in older adults with locally advanced NSCLC, and promising activity was observed.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"2128-2135"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging. 正在接受抗血栓治疗的肺结节患者经皮活检和微波消融的安全性和有效性：利伐沙班桥接研究。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-10-01 Epub Date: 2024-08-18 DOI: 10.1111/1759-7714.15425

Nan Wang, Tianyu Xue, Wenwen Zheng, Zhongying Shao, Zhuang Liu, Faliang Dai, Qi Xie, Jing Sang, Xin Ye

{"title":"Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging.","authors":"Nan Wang, Tianyu Xue, Wenwen Zheng, Zhongying Shao, Zhuang Liu, Faliang Dai, Qi Xie, Jing Sang, Xin Ye","doi":"10.1111/1759-7714.15425","DOIUrl":"10.1111/1759-7714.15425","url":null,"abstract":"Background: To evaluate the safety and efficacy of percutaneous biopsy and microwave ablation (B + MWA) in patients with pulmonary nodules (PNs) who are receiving antithrombotic therapy by rivaroxaban as bridging therapy.Methods: The study comprised 187 patients with PNs who underwent 187 B + MWA sessions from January 1, 2020, to December 31, 2021. The enrolled patients were divided into two groups: Group A, who received antithrombotic therapy five days before the procedure and received rivaroxaban as a bridging drug during hospitalization, and group B, who had no antithrombotic treatment. Information about the technical success rate, positive biopsy rate, complete ablative rate, and major complications were collected and analyzed.Results: Group A comprised 53 patients and group B comprised 134 patients. The technical success rate was 100% in both groups. The positive biopsy rates were 88.68% and 91.04%, respectively (p = 0.6211, X2 = 0.2443). In groups A and B, the complete ablative rates at 6, 12, and 24 months were 100.0% versus 99.25%, 96.23% versus 96.27%, and 88.68% versus 89.55%, respectively. There were no significant differences in bleeding and thrombotic complications between the two groups. No grade 5 complications occurred.Conclusions: It is generally considered safe and effective that patients who are on antithrombotic therapy by rivaroxaban as bridging to undergo B + MWA for treating PNs.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1989-1999"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.1111/1759-7714.15426

Evgenii Skurikhin, Mariia Zhukova, Natalia Ermakova, Edgar Pan, Darius Widera, Lubov Sandrikina, Lena Kogai, Nikolai Kushlinskii, Aslan Kubatiev, Sergey Morozov, Alexander Dygai

{"title":"Age-related features of lung cancer treatment using reprogrammed CD8 positive T cells in mice subjected to injection of Lewis lung carcinoma cells.","authors":"Evgenii Skurikhin, Mariia Zhukova, Natalia Ermakova, Edgar Pan, Darius Widera, Lubov Sandrikina, Lena Kogai, Nikolai Kushlinskii, Aslan Kubatiev, Sergey Morozov, Alexander Dygai","doi":"10.1111/1759-7714.15426","DOIUrl":"10.1111/1759-7714.15426","url":null,"abstract":"Background: Awareness of age-related features of carcinogenesis and the importance of cellular immunity is crucial for developing effective antitumor therapies for specific patient groups.Methods: In this study, we examined different populations of cancer stem cells (CSCs) and circulating tumor cells (CTCs) in \"young\" (8-10 weeks) and \"aged\" (80-82 weeks) C57BL/6 male mice. We used an orthotopic model of Lewis lung carcinoma (LLC) to evaluate the effectiveness of cell therapy targeting lung cancer through reprogrammed CD8-positive T cells (rCD8+ T cells) in mice from two different ages.Results: The findings revealed that tumor progression with age is primarily caused by impaired recruitment of T cells to the lungs. Additionally, a lower number of CTCs and CSCs were observed in younger mice compared to the older mice. The antitumor effect of rCD8+ T cells in aged mice was found to be inferior to that in young mice, which can be attributed to the reduced impact of therapy on specific CSCs populations.Conclusions: These results offer new insights into the treatment of lung cancer using rCD8+ T cells. Considering the age-related characteristics influencing disease progression, this therapy has the potential to significantly enhance the effectiveness of treatment methods.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"2000-2020"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to "Gentiana macrophylla flavonoids from Tibetan medicine decreases circ_0059665 to alleviate the progression of non-small cell lung cancer under hypoxia". 更正 "藏药中的大叶龙胆黄酮降低circ_0059665，缓解缺氧状态下非小细胞肺癌的进展"。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-10-01 Epub Date: 2024-09-01 DOI: 10.1111/1759-7714.15441

引用次数: 0

miR‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway miR-30c-5p 通过抑制 PI3K/AKT 信号通路抑制食管鳞状细胞癌的进展

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-18 DOI: 10.1111/1759-7714.15427

Haochun Shi, Binyang Pan, Jiaqi Liang, Benjie Cai, Gujie Wu, Yunyi Bian, Guangyao Shan, Shencheng Ren, Yiwei Huang, Weigang Guo

{"title":"miR‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway","authors":"Haochun Shi, Binyang Pan, Jiaqi Liang, Benjie Cai, Gujie Wu, Yunyi Bian, Guangyao Shan, Shencheng Ren, Yiwei Huang, Weigang Guo","doi":"10.1111/1759-7714.15427","DOIUrl":"https://doi.org/10.1111/1759-7714.15427","url":null,"abstract":"BackgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors, with high incidence and poor prognosis. Revealing mechanisms of ESCC progression and developing new therapeutic targets remains crucial. The aim of this study was to elucidate the molecular mechanism of miR‐30c‐5p in regulating the malignant progression of ESCC.MethodsTCGA, GEO, and other datasets were used to analyze the differential expression of miR‐30c‐5p in ESCC and adjacent tissues, and its impact on prognosis. Then the effects of miR‐30c‐5p on the proliferation, migration, and invasion of TE‐1 and Eca9706 cells were investigated through proliferation experiments, transwell and wounding healing assays. The regulatory mechanism of miR‐30c‐5p on the PI3K/AKT signaling pathway and its interaction in cancer progression were investigated through Western blots, dual‐luciferase reporter assay, and rescue experiments.ResultsmiR‐30c‐5p was significantly downregulated in ESCC tissue and represented a poor prognosis. miR‐30c‐5p mimic significantly inhibited the proliferation, migration, and invasion ability of ESCC, while miR‐30c‐5p inhibitor significantly promoted tumor cell progression. Through bioinformatic analysis and experimental results, miR‐30c‐5p interacted directly with PIK3CA mRNA and inhibited subsequent signaling pathway activation. PIK3CA activator could eliminate the inhibitory effects of miR‐30c‐5p mimic on the progression of ESCC, while PIK3CA inhibitors could rescue the promoting effect of miR‐30c‐5p inhibitor group cells.ConclusionsIn summary, we found that miR‐30c‐5p inhibited the proliferation, invasion and migration of ESCC by inhibiting PI3K/AKT signaling pathway for the first time, and this study is expected to provide a novel insight and potential therapeutic target for managing ESCC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"1 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142257028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton therapy for breast cancer: Reducing toxicity 质子治疗乳腺癌：减少毒性

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-14 DOI: 10.1111/1759-7714.15451

Kailin Qiao, Yuchun Wei, Cheng Tao, Jian Zhu, Shuanghu Yuan

引用次数: 0

Cytomegalovirus tracheobronchitis mimicking lung cancer progression in a patient with lung adenocarcinoma: A case report 一名肺腺癌患者模拟肺癌进展的巨细胞病毒气管支气管炎：病例报告

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-14 DOI: 10.1111/1759-7714.15446

Green Hong, Sung Joon Han, Kyung‐Hee Kim, Dongil Park, Chaeuk Chung

引用次数: 0

Left pulmonary vein anatomical variation in Turner syndrome. Benefits of three‐dimensional visualization for surgical planning 特纳综合征的左肺静脉解剖变异。三维可视化对手术规划的益处

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-11 DOI: 10.1111/1759-7714.15422

Gabrielle Drevet, Valentin Soldea, François Tronc

引用次数: 0

Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation 重温 ALK (D5F3) 免疫组化：洞察病灶染色和神经内分泌分化

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-11 DOI: 10.1111/1759-7714.15445

Yeoun Eun Sung, Meejeong Kim

{"title":"Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation","authors":"Yeoun Eun Sung, Meejeong Kim","doi":"10.1111/1759-7714.15445","DOIUrl":"https://doi.org/10.1111/1759-7714.15445","url":null,"abstract":"BackgroundScreening for anaplastic lymphoma kinase (ALK) rearranged non‐small cell lung cancer (NSCLC) is crucial for identifying patients eligible for targeted therapy. The FDA‐approved ALK (D5F3) immunohistochemistry (IHC) assay, used with the OptiView Amplification Kit, demonstrates excellent sensitivity and specificity in detecting these patients. However, the clinical significance of resulting focal positivity remains unclear, and ALK (D5F3) expression unrelated to ALK fusion is observed in some cases of neuroendocrine differentiation. This study aims to validate these findings with molecular testing and contribute to the accurate interpretation of ALK (D5F3) IHC results.MethodsA total of 1619 patients diagnosed with NSCLC and neuroendocrine carcinoma were evaluated using ALK (D5F3) IHC. For cases with strong but focal expression and those with diffuse strong positivity in neuroendocrine differentiation, ALK fluorescence in situ hybridization (FISH) and/or next‐generation sequencing (NGS) tests were performed.ResultsSeven out of 1109 adenocarcinomas (0.6%) and six out of 289 squamous cell carcinomas (2.1%) exhibited strong focal ALK (D5F3) expression. Nine out of 209 neuroendocrine carcinomas (4.3%) showed homogeneously strong ALK (D5F3) expression. All these cases, including adenocarcinoma with neuroendocrine differentiation and combined small cell carcinoma, were negative for ALK fusions by FISH and/or NGS.ConclusionThis study demonstrates that strong but focal ALK (D5F3) immunostaining and strong expression in neuroendocrine differentiation may not indicate ALK fusion. By considering these findings, we can improve the accuracy of patient selection for targeted therapy by minimizing false‐positive interpretations of ALK (D5F3) staining.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"22 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of survivals between sublobar resection and lobar resection for patients with clinical stage I non‐small cell lung cancer and interstitial lung disease: a propensity score matching analysis 临床 I 期非小细胞肺癌合并间质性肺病患者叶下切除术和叶状切除术的生存率比较：倾向得分匹配分析

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-09 DOI: 10.1111/1759-7714.15418

Ryohei Matsushima, Kosuke Fujino, Yamato Motooka, Hiroyuki Yamada, Chika Shirakami, Yusuke Shinchi, Hironobu Osumi, Tatsuya Yamada, Kentaro Yoshimoto, Koei Ikeda, Ichiro Kubota, Makoto Suzuki

{"title":"Comparison of survivals between sublobar resection and lobar resection for patients with clinical stage I non‐small cell lung cancer and interstitial lung disease: a propensity score matching analysis","authors":"Ryohei Matsushima, Kosuke Fujino, Yamato Motooka, Hiroyuki Yamada, Chika Shirakami, Yusuke Shinchi, Hironobu Osumi, Tatsuya Yamada, Kentaro Yoshimoto, Koei Ikeda, Ichiro Kubota, Makoto Suzuki","doi":"10.1111/1759-7714.15418","DOIUrl":"https://doi.org/10.1111/1759-7714.15418","url":null,"abstract":"BackgroundPatients with early‐stage lung cancer and interstitial lung disease have a poorer prognosis than those without interstitial lung disease. This study aimed to compare the long‐term outcomes of lobar and sublobar resections in these patients.MethodsWe retrospectively analyzed 138 consecutive patients with clinical stage I non‐small cell lung cancer and interstitial lung disease who underwent surgical treatment at two institutions between January 2010 and December 2020. Propensity score matching analysis was performed to adjust for baseline characteristics.ResultsThirty‐six patients underwent sublobar resection and 102 underwent lobar resection. The median follow‐up was 45.7 months. In all patients, 5‐year overall survival (OS) rates were 33.2% and 73.2%, and 5‐year recurrence‐free survival (RFS) rates were 24.2% and 60.1% in the sublobar and lobar resection groups, respectively (p < 0.01, <0.01). Death due to lung cancer and locoregional recurrence were significantly more frequent in the sublobar resection group than in the lobar resection group (p = 0.034, <0.01, respectively). On propensity score matching analysis, the 5‐year OS rates of the 19 matched pairs were 46.3% and 73.2%, and the RFS rates were 31.6% and 67.6% in the sublobar and lobar resection groups, respectively (p = 0.036, <0.01). The Cox proportional hazards model demonstrated a significant association between lobar resection and improved survival (p = 0.047).ConclusionThe patients in the lobar resection group had better survival rates than those in the sublobar resection group. In terms of long‐term prognosis, deliberately limited surgery may not be necessary for patients who tolerate lobectomy.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":"7 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0